Correlation of Oncotype Dx With Image Features and Molecular Characteristics of Breast Cancer
- To characterize differences in tumor morphology and molecular features that exist in
good- and poor-prognosis breast cancer as determined by Oncotype Dx assay (a reverse
- To develop a computer-aided design (CAD)-based system of analysis of digitized
histological images that would perform as well as Oncotype Dx assay in stratifying
estrogen receptor-positive (ER+) breast cancer into prognostic categories.
- To identify new therapeutic targets in the PI3-kinase signaling pathway for a subset of
poor-prognosis ER+ breast cancers.
OUTLINE: Patients who had Oncotype Dx assay (a reverse transcriptase-PCR-based assay)
performed for their breast cancer are identified by review of medical records. Diagnostic
H&E stained tumor tissue samples are reviewed by a pathologist. Relevant pathologic features
of the tumor (size, stage, grade, estrogen receptor, progesterone receptor, and HER2
staining) and linked Oncotype Dx score are recorded.
The H&E stained tumor tissue samples are scanned to create high-resolution digital images.
The images from each tissue sample are subjected to image analysis algorithms to identify
sets of image features that most clearly separate tumors with low recurrence scores from
those with high recurrence scores.
Unstained paraffin sections from each tumor tissue sample, when available, are processed
using IHC to analyze PI3-kinase signaling pathway (PTEN expression). Staining for other
components of the PI3-kinase signaling pathway, phospo-AKT, and other proteins of interest
is also performed. DNA is extracted from the samples and subjected to pyrosequencing
analysis on exons 9 and 20 of PI3KCA. Sequencing of other relevant potential oncogenes, such
as AKT, is also performed. Statistical analysis is performed to look for a correlation
between Oncotype Dx scores and the presence of PI3KCA mutations and/or loss of PTEN
Observational Model: Cohort, Time Perspective: Retrospective
Differences in tumor morphology and molecular features that exist in good- and poor-prognosis breast cancer as determined by Oncotype Dx assay
Shridar Ganesan, MD
Cancer Institute of New Jersey
United States: Institutional Review Board
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|